Drugs / CKD-706
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07358156 | Feb → Nov 2026 expected | atopic eczema | Chong Kun Dang Pharmaceutical | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-01-14 | Chong Kun Dang Pharmaceutical | Regulatory 종근당, 듀피젠트 바이오시밀러 유럽 최초 임상 1상 승인 ckdpharm.com ↗
종근당(대표 김영주)은 유럽의약품청(EMA) 및 영국 의약품규제청(MHRA)로부터 듀피젠트(성분명 두필루맙, Dupilumab) 바이오시밀러 ‘CKD-706’이 유럽 최초로 임상 1상 승인을 받았다고 14일 밝혔다. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-01-14 | Chong Kun Dang Pharmaceutical | 종근당, 듀피젠트 바이오시밀러 유럽 최초 임상 1상 승인 ckdpharm.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CKD-706 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07358156 ↗ |
| Route | Subcutaneous | “One subcutaneous dose of CKD-706 in pre-filled syringe, 300 mg/2mL” NCT07358156 ↗ |